etrolizumab (RG7413) - Roche
Etrolizumab: Final data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021 (Roche) - Sep 15, 2020 - Roche Pharma Day 2020 
P3 data • Crohn's disease • Inflammatory Bowel Disease
https://www.roche.com/dam/jcr:7f4a9ab6-60e2-4a69-98f1-1794916cc91d/en/irp20200914-immunology-ophthalmology-infectious-disease.pdf
 
Sep 15, 2020
 
 
bf6c698c-f3d4-491d-b041-d1b18cce915a.png